(43 days)
Not Found
No
The description focuses on automated biochemical and turbidity measurements and comparison to reference methods, with no mention of AI or ML algorithms for interpretation.
No
This device is for in vitro diagnostic testing, specifically for identifying microorganisms and determining their susceptibility to antimicrobial agents. It does not directly treat or diagnose a disease in a living patient, which is characteristic of therapeutic devices.
Yes
The device is intended for the rapid identification and in vitro antimicrobial susceptibility testing of isolates, which are diagnostic activities. It determines minimum inhibitory concentration (MIC) values and category interpretations (sensitive, intermediate, or resistant), all of which are crucial for diagnosing bacterial infections and guiding treatment.
No
The device description explicitly lists hardware components (BD Phoenix instrument, BD Phoenix panels, BD Phoenix ID Broth, BD Phoenix AST Broth, BD Phoenix AST Indicator solution) in addition to software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the system is intended for "in vitro antimicrobial susceptibility testing of isolates from pure culture of most aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria of human origin." The term "in vitro" is a key indicator of an IVD.
- Device Description: The description details a system that analyzes biological samples (bacterial isolates) outside of the human body to provide information about their characteristics (identification and susceptibility to antimicrobial agents). This is the core function of an IVD.
- Testing Method: The description mentions "broth based microdilution test" and the use of "biochemicals for organism ID testing and antimicrobial agents for AST determinations." These are standard laboratory techniques used in IVD testing.
- Output: The system provides "identification of the isolate, minimum inhibitory concentration (MIC) values and category interpretations (S, I, or R)." These are diagnostic results derived from testing the sample in vitro.
The entire document describes a system designed to perform diagnostic tests on biological samples in a laboratory setting, which aligns perfectly with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The BD PhoenixTM Automated Microbiology System is intended for the rapid identification and in vitro antimicrobial susceptibility testing of isolates from pure culture of most aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria of human origin.
The BD Phoenix™ Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus and Streptococcus.
This premarket notification is for ceftazidime at concentrations of 0.5-64 µg/mL to Gram-negative ID/AST or AST only Phoenix panels with the removal of the limitations for Citrobacter freundii and Stenotrophomonas maltophilia. Ceftazidime has been shown to be active in vitro against most strains of microorganisms listed below, as described in the FDA-approved package insert for this antimicrobial agent.
Active In Vitro and in Clinical Infections Against:
Escherichia coli
Citrobacter spp., including Citrobacter freundii and Citrobacter koseri (formerly C. diversus)
Enterobacter spp., including Enterobacter cloacae and Enterobacter aerogenes
Active In Vitro:
Acinetobacter spp.
Morganella morganii
Providencia spp., including Providencia rettgeri
Klebsiella spp., including Klebsiella pneumoniae
Proteus mirabilis
Proteus vulgaris
Pseudomonas spp., including Pseudomonas aeruginosa
Serratia spp.
Salmonella spp.
Shigella spp.
Product codes (comma separated list FDA assigned to the subject device)
LON
Device Description
The BD Phoenix Automated Microbiology System (Phoenix System) is an automated system for the rapid identification (ID) and antimicrobial susceptibility testing (AST) of clinically relevant bacterial isolates. The system includes the following components:
- . BD Phoenix instrument and software.
- BD Phoenix panels containing biochemicals for organism ID testing and antimicrobial agents . for AST determinations.
- BD Phoenix ID Broth used for performing ID tests and preparing AST Broth inoculum. .
- BD Phoenix AST Broth used for performing AST tests only. .
- BD Phoenix AST Indicator solution added to the AST Broth to aid in bacterial growth . determination.
The Phoenix AST method is a broth based microdilution test. The Phoenix system utilizes a redox indicator for the detection of organism growth in the presence of an antimicrobial agent. Measurements of changes to the indicator as well as bacterial turbidity are used in the determination of bacterial growth. Each AST panel configuration contains several antimicrobial agents with a wide range of two-fold doubling dilution concentrations.
The Phoenix panel is a sealed and self-inoculating molded polystyrene tray with 136 micro-wells containing dried reagents. Organisms for susceptibility testing must be a pure culture and preliminarily identified as a Gram-negative or Gram-positive isolate. Phoenix panels are inoculated with a specified organism density and placed in the instrument.
The instrument houses the panels where they are continuously incubated at a nominal temperature of 35°C. The instrument takes readings of the panels every 20 minutes. The readings are interpreted to give an identification of the isolate, minimum inhibitory concentration (MIC) values and category interpretations. S. I, or R (sensitive, intermediate, or resistant).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Clinical, stock and challenge isolates were tested across multiple geographically diverse sites across the United States to demonstrate the performance of the Phoenix antimicrobial susceptibility test with the Gram-negative Phoenix panel format containing this antimicrobial agent. Phoenix System results for Challenge set isolates were compared to the expected results. Phoenix System results for clinical isolates were compared to the results obtained from the CLSI reference broth microdilution method.
The performance of the Phoenix System was assessed by calculating Essential Agreement (EA) and Category Agreement (CA) to expected/reference results for all isolates tested.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The BD Phoenix™ Automated Microbiology System demonstrated substantially equivalent performance when compared with the CLSI (formerly NCCLS) reference broth microdilution method.
The BD Phoenix™ Automated Microbiology System has demonstrated substantially equivalent performance when compared to the CLSI reference broth microdilution method (AST panels prepared according to CLSI M7). The system has been evaluated as defined in the FDA guidance document, "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA'', February 5, 2003.
Clinical, stock and challenge isolates were tested across multiple geographically diverse sites across the United States to demonstrate the performance of the Phoenix antimicrobial susceptibility test with the Gram-negative Phoenix panel format containing this antimicrobial agent. Phoenix System results for Challenge set isolates were compared to the expected results. Phoenix System results for clinical isolates were compared to the results obtained from the CLSI reference broth microdilution method.
The performance of the Phoenix System was assessed by calculating Essential Agreement (EA) and Category Agreement (CA) to expected/reference results for all isolates tested. Essential Agreement (EA) occurs when the BD Phoenix™ Automated Microbiology System agrees exactly or within ± one two-fold dilution to the reference result. Category Agreement (CA) occurs when the BD Phoenix™ Automated Microbiology System agrees with the reference method with respect to the FDA categorical interpretive criteria (susceptible, intermediate, and resistant).
Accuracy:
Ceftazidime: EA (n=2388) = 96.6%, CA (n=2388) = 94.7%
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Essential Agreement (EA) occurs when the BD Phoenix™ Automated Microbiology System agrees exactly or within ± one two-fold dilution to the reference result.
Category Agreement (CA) occurs when the BD Phoenix™ Automated Microbiology System agrees with the reference method with respect to the FDA categorical interpretive criteria (susceptible, intermediate, and resistant).
For Ceftazidime (0.5 - 64 μg/mL): EA (%) = 96.6, CA (%) = 94.7
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
VITEK® System (PMA No. N50510), K020321, K033560, K041384
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.
(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
0
510(K) SUMMARY
| 510(K) SUMMARY | K063573 | |
|---|---|---|
| SUBMITTED BY: | Becton, Dickinson and Company | |
| 7 Loveton Circle | ||
| Sparks, MD 21152 | ||
| Phone: 410-316-4161 | ||
| Fax: (410)-316-4499 | ||
| JAN 11 2007 | ||
| CONTACT NAME: | Vicki Kennedy Whitely | |
| Regulatory Affairs Specialist | ||
| DATE PREPARED: | November 28, 2006 | |
| DEVICE TRADE NAME: | BD PhoenixTM Automated Microbiology System – | |
| Ceftazidime 0.5-64 µg/mL | ||
| DEVICE COMMON NAME: | Antimicrobial susceptibility test system-short incubation | |
| DEVICE CLASSIFICATION: | Fully Automated Short-Term Incubation Cycle Antimicrobial | |
| Susceptibility Device, 21 CFR 866.1645 | ||
| PREDICATE DEVICES: | VITEK® System (PMA No. N50510) and BD PhoenixTM | |
| Automated Microbiology System with Gatifloxacin (K020321, | ||
| May 23, 2002), Ceftazidime (K033560, January 14, 2004 and | ||
| K041384, August 3, 2004). | ||
| INTENDED USE: | The BD PhoenixTM Automated Microbiology System is | |
| intended for the rapid identification and in vitro antimicrobial | ||
| susceptibility testing of isolates from pure culture of most | ||
| aerobic and facultative anaerobic Gram-negative and Gram- | ||
| positive bacteria of human origin |
DEVICE DESCRIPTION:
The BD Phoenix Automated Microbiology System (Phoenix System) is an automated system for the rapid identification (ID) and antimicrobial susceptibility testing (AST) of clinically relevant bacterial isolates. The system includes the following components:
- . BD Phoenix instrument and software.
- BD Phoenix panels containing biochemicals for organism ID testing and antimicrobial agents . for AST determinations.
- BD Phoenix ID Broth used for performing ID tests and preparing AST Broth inoculum. .
- BD Phoenix AST Broth used for performing AST tests only. .
- BD Phoenix AST Indicator solution added to the AST Broth to aid in bacterial growth . determination.
1
The Phoenix AST method is a broth based microdilution test. The Phoenix system utilizes a redox indicator for the detection of organism growth in the presence of an antimicrobial agent. Measurements of changes to the indicator as well as bacterial turbidity are used in the determination of bacterial growth. Each AST panel configuration contains several antimicrobial agents with a wide range of two-fold doubling dilution concentrations.
The Phoenix panel is a sealed and self-inoculating molded polystyrene tray with 136 micro-wells containing dried reagents. Organisms for susceptibility testing must be a pure culture and preliminarily identified as a Gram-negative or Gram-positive isolate. Phoenix panels are inoculated with a specified organism density and placed in the instrument.
The instrument houses the panels where they are continuously incubated at a nominal temperature of 35°C. The instrument takes readings of the panels every 20 minutes. The readings are interpreted to give an identification of the isolate, minimum inhibitory concentration (MIC) values and category interpretations. S. I, or R (sensitive, intermediate, or resistant).
DEVICE COMPARISON:
The BD Phoenix™ Automated Microbiology System demonstrated substantially equivalent performance when compared with the CLSI (formerly NCCLS) reference broth microdilution method. This premarket notification provides data for the limitations for Citrobacter freundii and Stenotrophomonas maltophilia with ceftazidime.
SUMMARY OF SUBSTANTIAL EQUIVALENCE TESTING:
The BD Phoenix™ Automated Microbiology System has demonstrated substantially equivalent performance when compared to the CLSI reference broth microdilution method (AST panels prepared according to CLSI M7). The system has been evaluated as defined in the FDA guidance document, "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA'', February 5, 2003.
2
Clinical Studies
Clinical, stock and challenge isolates were tested across multiple geographically diverse sites across the United States to demonstrate the performance of the Phoenix antimicrobial susceptibility test with the Gram-negative Phoenix panel format containing this antimicrobial agent. Phoenix System results for Challenge set isolates were compared to the expected results. Phoenix System results for clinical isolates were compared to the results obtained from the CLSI reference broth microdilution method.
The performance of the Phoenix System was assessed by calculating Essential Agreement (EA) and Category Agreement (CA) to expected/reference results for all isolates tested. Essential Agreement (EA) occurs when the BD Phoenix™ Automated Microbiology System agrees exactly or within ± one two-fold dilution to the reference result. Category Agreement (CA) occurs when the BD Phoenix™ Automated Microbiology System agrees with the reference method with respect to the FDA categorical interpretive criteria (susceptible, intermediate, and resistant).
Table 1 summarizes the performance for the isolates tested in this study.
Performance of BD Phoenix System for Gram-Negative Organisms by Drug Table 1:
| Company of the comments of controlled on the continued to the comments of the
ntimicrobia | Children and the continued to the country of
Acres of each and and the
oncentration | AutoPMACAGATAA
Company of Children Company of Children Company of Children Company of Children Company of Children Company of Children Company of Children Comments of the Children
10-40 | A Channel Court Children Children a | of the firm finance of Act Act Act Act Act A CLASS of
10.00 | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------------------------------------------------------|--|
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
tazıdıme
And I manuel a provent on | AND AND OF CHILIP THE THE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAST LE LEAS
| 1000
R LEE MI DE BILLERS | | 0000
i | |
Conclusions Drawn from Substantial Equivalence Studies
The data collected from the substantial equivalence studies demonstrate that testing on the BD Phoenix™ Automated Microbiology System with this antimicrobial agent is substantially equivalent as outlined in the FDA guidance document, "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA", February 5, 2003. Technological characteristics of this system are substantially equivalent to those used in the VITEK® system, which received approval by the FDA under PMA number N50510 and BD Phoenix™ Automated Microbiology System with Gatifloxacin (K020321, May 23, 2002), and with Ceftazidime (K033560, January 14, 2004 and K041384, August 3, 2004).
3
SUMMARY INFORMATION FOR CEFTAZIDIME Available Range 0.5 - 64 µg/mL
Performance
Accuracy
| Antimicrobial | Concentration | EA (n) | EA (%) | CA (n) | CA (%) |
|---|---|---|---|---|---|
| Ceftazidime | 0.5 - 64 μg/mL | 2388 | 96.6 | 2388 | 94.7 |
Breakpoints - CLSI
| Organism | S | I | R |
|---|---|---|---|
| Enterobacteriaceae | $ \le 8 $ | 16 | $ \ge32 $ |
| Pseudomonas aeruginosa and | |||
| other Non-Enterobacteriaceae | $ \le 8 $ | 16 | $ \ge32 $ |
Recommended Quality Control Organisms
| Quality Control Strain | MIC Range | Source |
|---|---|---|
| Escherichia coli ATCC 25922 | 0.06-0.5 $ μg/mL $ | CLSI |
| Pseudomonas aeruginosa ATCC 27853 | 1-4 $ μg/mL $ | CLSI |
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three curved lines representing its wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - U.S.A." is arranged in a circular pattern around the eagle.
Re:
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Vicki Kennedy Whitley Regulatory Affairs Specialist BD Diagnostics Systems Becton, Dickinson and Company 7 Loveton Circle Sparks, MD 21152
JAN 1 1 2007
K063573 Trade/Device Name: BD Phoenix™ Automated Microbiology System Ceftazidime (0.5-64 µg/mL) – Gram-Negative ID/AST or AST Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices Regulatory Class: Class II Product Code: LON Dated: November 28, 2006 Received: November 29, 2006
Dear Ms. Whitley:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your 1 vire can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
5
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Sally, autumn
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Page 1 of 1
510(k) Number: K063573
Device Name: BD Phoenix™ Automated Microbiology System for use with the antimicrobial agent ceftazidime (0.5-64 ug/mL) - Gram-Negative ID/AST or AST only Phoenix panels with the removal of the limitations for Citrobacter freundii and Stenotrophomonas maltophilia.
Indications for Use:
The BD Phoenix™ Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus and Streptococcus.
This premarket notification is for ceftazidime at concentrations of 0.5-64 µg/mL to Gram-negative ID/AST or AST only Phoenix panels with the removal of the limitations for Citrobacter freundii and Stenotrophomonas maltophilia. Ceftazidime has been shown to be active in vitro against most strains of microorganisms listed below, as described in the FDA-approved package insert for this antimicrobial agent.
Escherichia coli
Active In Vitro and in Clinical Infections Against:
Citrobacter spp., including Citrobacter freundii and Citrobacter koseri (formerly C. diversus) Enterobacter spp., including Enterobacter cloacae and Enterobacter aerogenes
Active In Vitro:
Acinetobacter spp. Morganella morganii Providencia spp., including Providencia rettgeri
Klebsiella spp., including Klebsiella pneumoniae Proteus mirabilis
Proteus vulgaris Pseudomonas spp., including Pseudomonas aeruginosa Serratia spp.
Salmonella spp. Shigella spp.
Prescription Use (Per 21 CFR 801.109)
Over-the-Counter Use
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Freddie Poole
Division Sign-Off
Division Sign-Off
office of In Vitro Diagnostic Device Evaluation and Safety
K06 3573